Drug Profile
Liraglutide biosimilar - CinnaGen
Alternative Names: CinnaGen-liraglutideLatest Information Update: 30 Sep 2023
Price :
$50
*
At a glance
- Originator CinnaGen
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2023 Drug is still in clinical development
- 28 Feb 2021 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus in Iran (SC, Injection)
- 02 Feb 2018 CinnaGen plans a phase III trial to compare the safety and efficacy of liraglutide biosimilar to liraglutide in patients with Type 2 diabetes mellitus (SC) in April 2018 (NCT03421119)